Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults.
<h4>Background</h4>Recombinant Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) formulated on Alhydrogel (Na-GST-1/Alhydrogel) is being developed to prevent anemia and other complications of N. americanus infection. Antibodies induced by vaccination with recombinant Na-GST-1 are...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-12-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://doi.org/10.1371/journal.pntd.0012788 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595712414580736 |
|---|---|
| author | David J Diemert Maria Zumer Mark Bova Christina Gibbs-Tewary Elissa M Malkin Doreen Campbell Lara Hoeweler Guangzhao Li Maria Elena Bottazzi Peter J Hotez Jeffrey M Bethony |
| author_facet | David J Diemert Maria Zumer Mark Bova Christina Gibbs-Tewary Elissa M Malkin Doreen Campbell Lara Hoeweler Guangzhao Li Maria Elena Bottazzi Peter J Hotez Jeffrey M Bethony |
| author_sort | David J Diemert |
| collection | DOAJ |
| description | <h4>Background</h4>Recombinant Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) formulated on Alhydrogel (Na-GST-1/Alhydrogel) is being developed to prevent anemia and other complications of N. americanus infection. Antibodies induced by vaccination with recombinant Na-GST-1 are hypothesized to interfere with the blood digestion pathway of adult hookworms in the host. Phase 1 trials have demonstrated the safety of Na-GST-1 formulated on Alhydrogel, but further optimization of the vaccine adjuvant formulation may improve humoral immune responses, thereby increasing the likelihood of vaccine efficacy.<h4>Methods</h4>A randomized, observer-blind, dose escalation Phase 1 trial was conducted in 24 healthy, hookworm-naïve adults. In each cohort of 12 participants, 4 were randomized to receive 100 µg of Na-GST-1/Alhydrogel and 8 to receive 30 µg or 100 µg of Na-GST-1/Alhydrogel plus the Cytosine-phospho-Guanine (CpG) oligodeoxynucleotide Toll-like receptor-9 agonist, CpG 10104, in the first and second cohorts, respectively. Progression to the second cohort was dependent upon evaluation of 7-day safety data after all participants in the first cohort had received the first dose of vaccine. Three intramuscular injections of study product were administered on days 0, 56, and 112, after which participants were followed for 6 months. IgG and IgG subclass antibody responses to Na-GST-1 were measured by qualified indirect ELISAs at pre- and post-vaccination time points.<h4>Results</h4>Na-GST-1/Alhydrogel administered with or without CpG 10104 was well-tolerated. The most common solicited adverse events were mild injection site tenderness and pain, and mild headache. There were no vaccine-related serious adverse events or adverse events of special interest. Both dose concentrations of Na-GST-1/Alhydrogel plus CpG 10104 had significantly higher post-vaccination levels of antigen-specific IgG antibody compared to Na-GST-1/Alhydrogel without CpG, starting after the second injection. Peak anti-Na-GST-1 IgG levels were observed between 2 and 4 weeks following the third dose, regardless of Na-GST-1 formulation. IgG levels decreased but remained significantly above baseline in all groups by day 290, at which point all participants (20 of 20 evaluable participants) still had detectable IgG. Longitudinal antigen-specific IgG1 and IgG3 subclass responses mirrored those of total IgG, whereas IgG4 responses were lower in the groups that received the vaccine with the CpG adjuvant compared to the non-CpG group.<h4>Conclusions</h4>Vaccination of hookworm-naïve adults with Na-GST-1/Alhydrogel plus CpG 10104 was safe and minimally reactogenic. Addition of CpG 10104 to Na-GST-1/Alhydrogel resulted in significant improvement in IgG responses against the vaccine antigen. These promising results have led to inclusion of the CpG 10104 formulation of Na-GST-1/Alhydrogel in a Phase 2 proof-of-concept controlled human infection trial. |
| format | Article |
| id | doaj-art-ccb8afd4b2a1414ea3eb54a742cb997c |
| institution | Kabale University |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-ccb8afd4b2a1414ea3eb54a742cb997c2025-01-18T05:31:42ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352024-12-011812e001278810.1371/journal.pntd.0012788Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults.David J DiemertMaria ZumerMark BovaChristina Gibbs-TewaryElissa M MalkinDoreen CampbellLara HoewelerGuangzhao LiMaria Elena BottazziPeter J HotezJeffrey M Bethony<h4>Background</h4>Recombinant Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) formulated on Alhydrogel (Na-GST-1/Alhydrogel) is being developed to prevent anemia and other complications of N. americanus infection. Antibodies induced by vaccination with recombinant Na-GST-1 are hypothesized to interfere with the blood digestion pathway of adult hookworms in the host. Phase 1 trials have demonstrated the safety of Na-GST-1 formulated on Alhydrogel, but further optimization of the vaccine adjuvant formulation may improve humoral immune responses, thereby increasing the likelihood of vaccine efficacy.<h4>Methods</h4>A randomized, observer-blind, dose escalation Phase 1 trial was conducted in 24 healthy, hookworm-naïve adults. In each cohort of 12 participants, 4 were randomized to receive 100 µg of Na-GST-1/Alhydrogel and 8 to receive 30 µg or 100 µg of Na-GST-1/Alhydrogel plus the Cytosine-phospho-Guanine (CpG) oligodeoxynucleotide Toll-like receptor-9 agonist, CpG 10104, in the first and second cohorts, respectively. Progression to the second cohort was dependent upon evaluation of 7-day safety data after all participants in the first cohort had received the first dose of vaccine. Three intramuscular injections of study product were administered on days 0, 56, and 112, after which participants were followed for 6 months. IgG and IgG subclass antibody responses to Na-GST-1 were measured by qualified indirect ELISAs at pre- and post-vaccination time points.<h4>Results</h4>Na-GST-1/Alhydrogel administered with or without CpG 10104 was well-tolerated. The most common solicited adverse events were mild injection site tenderness and pain, and mild headache. There were no vaccine-related serious adverse events or adverse events of special interest. Both dose concentrations of Na-GST-1/Alhydrogel plus CpG 10104 had significantly higher post-vaccination levels of antigen-specific IgG antibody compared to Na-GST-1/Alhydrogel without CpG, starting after the second injection. Peak anti-Na-GST-1 IgG levels were observed between 2 and 4 weeks following the third dose, regardless of Na-GST-1 formulation. IgG levels decreased but remained significantly above baseline in all groups by day 290, at which point all participants (20 of 20 evaluable participants) still had detectable IgG. Longitudinal antigen-specific IgG1 and IgG3 subclass responses mirrored those of total IgG, whereas IgG4 responses were lower in the groups that received the vaccine with the CpG adjuvant compared to the non-CpG group.<h4>Conclusions</h4>Vaccination of hookworm-naïve adults with Na-GST-1/Alhydrogel plus CpG 10104 was safe and minimally reactogenic. Addition of CpG 10104 to Na-GST-1/Alhydrogel resulted in significant improvement in IgG responses against the vaccine antigen. These promising results have led to inclusion of the CpG 10104 formulation of Na-GST-1/Alhydrogel in a Phase 2 proof-of-concept controlled human infection trial.https://doi.org/10.1371/journal.pntd.0012788 |
| spellingShingle | David J Diemert Maria Zumer Mark Bova Christina Gibbs-Tewary Elissa M Malkin Doreen Campbell Lara Hoeweler Guangzhao Li Maria Elena Bottazzi Peter J Hotez Jeffrey M Bethony Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. PLoS Neglected Tropical Diseases |
| title | Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. |
| title_full | Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. |
| title_fullStr | Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. |
| title_full_unstemmed | Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. |
| title_short | Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults. |
| title_sort | randomized observer blind controlled phase 1 study of the safety and immunogenicity of the na gst 1 alhydrogel hookworm vaccine with or without a cpg odn adjuvant in hookworm naive adults |
| url | https://doi.org/10.1371/journal.pntd.0012788 |
| work_keys_str_mv | AT davidjdiemert randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT mariazumer randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT markbova randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT christinagibbstewary randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT elissammalkin randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT doreencampbell randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT larahoeweler randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT guangzhaoli randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT mariaelenabottazzi randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT peterjhotez randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults AT jeffreymbethony randomizedobserverblindcontrolledphase1studyofthesafetyandimmunogenicityofthenagst1alhydrogelhookwormvaccinewithorwithoutacpgodnadjuvantinhookwormnaiveadults |